Madrigal Pharmaceuticals heads into the post-earnings stretch with short sellers retreating and the Street turning incrementally more constructive — the tension being that even after a 6.4% earnings-day pop, shorts remain historically large at 17% of the float.
The clearest positive development this week came from analysts. Truist Securities raised its price target to $709 from $640 on May 13, keeping its Buy rating, a direct response to the strong Q1 print — Rezdiffra net sales beat expectations and drove the top line. That move puts Truist well above the current price of $510.26. Most other active firms stayed constructive too: Evercore ISI (Outperform) and Canaccord Genuity (Buy) both trimmed their targets modestly to $649 and $578 respectively after the report, likely factoring in the MASH competitive landscape and the still-unclear commercial trajectory with ARO-PNPLA3. The mean analyst target across the coverage universe is $674, implying roughly 30% upside. Only Bank of America sits at Neutral, with a $529 target — a meaningful outlier below consensus and close to where the stock already trades. The net read from the Street is broadly positive, but the wide target dispersion reflects genuine uncertainty about how fast Rezdiffra can convert addressable patients into paying prescriptions.
Short sellers are modestly backing away, but the position is still substantial. Short interest fell nearly 5% on the week to 17% of the free float — a reduction of roughly 190,000 shares over five sessions. That unwind follows a brief buildup through late April that pushed the position above 4 million shares. Cost to borrow has barely moved; at 0.47%, it remains ultra-cheap, meaning shorts face almost no carry pressure. Borrow availability is plentiful — nothing in the lending market suggests any near-term squeeze dynamic. The ORTEX short score of 68.6 is elevated and has been essentially flat for two weeks, reinforcing that the short thesis hasn't changed materially. The position reflects a structural bear case, not panic hedging.
Options positioning has edged more defensive than usual. The put/call ratio is running at 0.37, about 1.4 standard deviations above its 20-day average of 0.29 — an uptick that followed the earnings beat rather than preceded it. The PCR remains well within the historical range (52-week high is 0.76), so this is mild caution rather than aggressive hedging. RSI14 at 49 is neutral; the stock hasn't broken decisively in either direction since the Q1 report.
Institutional ownership is concentrated. The top five holders — Baker Bros., RTW Investments, Vanguard, Avoro Capital, and Paulson & Co — collectively hold around 40% of shares outstanding. Vanguard added 121,000 shares through Q1, Wellington added 203,000, and BlackRock added 85,000 in April. These are passive and semi-passive flows, but the direction is incrementally supportive. The most recent insider activity on record is from March 6, when the CEO, CFO, and founder each sold relatively small positions at prices around $430 — well below current levels — making those sales routine compensation-related events rather than a signal.
The Q1 earnings print itself produced a +6.4% day-one move, and the Q4 print in February was essentially flat (-0.3% day-one). The next earnings event is scheduled for June 17. That gives the stock about five weeks to either close the gap to analyst targets or let the structural short position rebuild further. The key variable to watch is Rezdiffra prescription data — any real-world dispensing update before the June call will likely matter more to sentiment than any macro backdrop.
See the live data behind this article on ORTEX.
Open MDGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
